GDRX
GoodRx Holdings, Inc.
$2.63
-0.75%
$890.7M
No data for this timeframe.
Vol
Market Cap$890.7M
Cap SizeSmall Cap
Analyst ConsensusHold (48%)
Inst. Holders8 funds
Inst. Value$40.0M
Inst. Activity2 buys / 3 sells
Reddit Sentiment67° Warm
SEC Reports4
Exchange Nasdaq·Sector Services-Computer Processing & Data Preparation·Inc. DE·CIK 0001809519·Prev Close $2.65
Recent Activity
May 27, 2026
Insider
Bruehlman Ronald E sold 4,642 shares
Director @ $0.00 ($0.00)
May 27, 2026
Insider
Hirsch Douglas Joseph sold 4,642 shares
Director @ $0.00 ($0.00)
May 27, 2026
short_volume
Short Volume: GDRX — 59.3% short (0.6M / 0.9M)
Short: 562,062 | Exempt: 129 | TRF Vol: 947,036 | Short Ratio: 59.3% | Off-exchange volume (dark poo
May 15, 2026
Insider
McGinnis Christopher A sold 44,779 shares
See Remarks @ $0.00 ($0.00)
May 6, 2026
SEC
GoodRx reported Q1 2026 revenue of $194.0M (-4% YoY), GAAP EPS of $0.00 (miss vs $0.03 consensus), and adjusted EBITDA o
8-K — Impact 5/10
Apr 24, 2026
SEC
GoodRx Holdings appointed Thomas Chan as Chief Accounting Officer, effective April 23, 2026. Chan, previously Vice Presi
8-K — Impact 3/10
Apr 3, 2026
SEC
GoodRx director Ian T. Clark resigned effective March 31, 2026, with no disagreement cited. CEO Wendy Barnes was reclass
8-K — Impact 2/10
Inst.
MORGAN STANLEY — DOUBLED
1,118,427 shares ($3.0M)
Price Targets
$3.18
+20.0% upside
Strong Buy
Current $2.65
Low $2.25
Median $3.00
High $4.00
13 analysts
$2.25
$4.00
Analyst Ratings
4Strong Buy
6Buy
9Hold
2Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 14, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| May 11, 2026 | TD Cowen | MAINTAIN | Buy → Buy |
| Mar 4, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| Mar 3, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Mar 2, 2026 | Goldman Sachs | MAINTAIN | Neutral → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.08 ▲ +1.3% | $0.07 — $0.11 | -10% YoY | 11 |
| Next Q | $0.08 ▼ -3.6% | $0.07 — $0.09 | 1% YoY | 11 |
| Current FY | $0.31 ▼ -1.9% | $0.29 — $0.35 | -11% YoY | 11 |
| Next FY | $0.36 ▼ -2.4% | $0.30 — $0.44 | 15% YoY | 12 |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $26.0M | — |
| RENAISSANCE TECHNOLOGIES LLC | $8.7M | — |
| MORGAN STANLEY | $3.0M | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $1.3M | NEW |
| WELLS FARGO & COMPANY/MN | $445.2K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 27, 2026 | Bruehlman Ronald | A | $0.00 |
| May 27, 2026 | Hirsch Douglas | A | $0.00 |
| May 15, 2026 | McGinnis Christopher | M | $0.00 |
| May 15, 2026 | McGinnis Christopher | F | $49.1K |
| May 15, 2026 | McGinnis Christopher | M | $0.00 |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
8 institutional holders with $40.0M total value (14,775,249 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, MORGAN. Net selling activity: 3 institutions trimmed/exited vs 2 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 9,584,183 | $26.0M | 64.9% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 3,210,938 | $8.7M | 21.7% | — |
| 3 | MORGAN STANLEY | 1,118,427 | $3.0M | 7.6% | DOUBLED +187.3% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 475,609 | $1.3M | 3.2% | NEW |
| 5 | WELLS FARGO & COMPANY/MN | 164,289 | $445.2K | 1.1% | DOUBLED +267.6% |
| 6 | TWO SIGMA INVESTMENTS, LP | 149,573 | $405.3K | 1.0% | TRIM -70.7% |
| 7 | BANK OF AMERICA CORP /DE/ | 65,967 | $178.8K | 0.4% | NEAR_EXIT -77.2% |
| 8 | FMR LLC | 6,263 | $17.0K | 0.0% | NEAR_EXIT -83.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | DOUBLED | 389,246 | 1,118,427 | +187.3% | $3.0M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 44,696 | 164,289 | +267.6% | $445.2K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 509,847 | 149,573 | -70.7% | $405.3K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 289,172 | 65,967 | -77.2% | $178.8K | 2025-Q4 |
| FMR LLC | NEAR_EXIT | 36,810 | 6,263 | -83.0% | $17.0K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 745,844 | 509,847 | -31.6% | $2.2M | 2025-Q3 |
| UBS Group AG | ADD | 274,940 | 405,651 | +47.5% | $1.7M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 447,205 | 289,172 | -35.3% | $1.2M | 2025-Q3 |
| FMR LLC | DOUBLED | 4,778 | 36,810 | +670.4% | $155.7K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 508,214 | 745,844 | +46.8% | $3.7M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 328,121 | 447,205 | +36.3% | $2.2M | 2025-Q2 |
| MORGAN STANLEY | TRIM | 730,040 | 432,279 | -40.8% | $2.2M | 2025-Q2 |
| UBS Group AG | TRIM | 439,377 | 274,940 | -37.4% | $1.4M | 2025-Q2 |
| FMR LLC | TRIM | 18,533 | 4,778 | -74.2% | $23.8K | 2025-Q2 |
| CITADEL ADVISORS LLC | ADD | 688,916 | 1,086,823 | +57.8% | $4.8M | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 330,065 | 730,040 | +121.2% | $3.2M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 722,374 | 508,214 | -29.6% | $2.2M | 2025-Q1 |
| UBS Group AG | ADD | 233,399 | 439,377 | +88.3% | $1.9M | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | ADD | 27,506 | 44,403 | +61.4% | $195.8K | 2025-Q1 |
| FMR LLC | DOUBLED | 665 | 18,533 | +2686.9% | $81.7K | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 421,494 | 688,916 | +63.4% | $3.2M | 2024-Q4 |
| UBS Group AG | DOUBLED | 99,145 | 233,399 | +135.4% | $1.1M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 108,960 | 27,506 | -74.8% | $127.9K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 480,123 | — | $3.3M | 2024-Q3 |
| MORGAN STANLEY | TRIM | 1,021,800 | 392,247 | -61.6% | $2.7M | 2024-Q3 |
7 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 27, 2026 | Bruehlman Ronald E | Director | A | 4,642 | $0.00 | $0.00 |
| May 27, 2026 | Hirsch Douglas Joseph | Director | A | 4,642 | $0.00 | $0.00 |
| May 15, 2026 | McGinnis Christopher A | See Remarks | M | 44,779 | $0.00 | $0.00 |
| May 15, 2026 | McGinnis Christopher A | See Remarks | F | 19,726 | $2.49 | $49.1K |
| May 15, 2026 | McGinnis Christopher A | See Remarks | M | 44,779 | $0.00 | $0.00 |
| May 15, 2026 | Chan Thomas (TC) | Chief Accounting Officer | M | 1,252 | $0.00 | $0.00 |
| May 15, 2026 | Chan Thomas (TC) | Chief Accounting Officer | F | 638 | $2.49 | $1.6K |
| May 15, 2026 | Chan Thomas (TC) | Chief Accounting Officer | M | 1,252 | $0.00 | $0.00 |
| May 11, 2026 | Chan Thomas (TC) | Chief Accounting Officer | A | 54,494 | $0.00 | $0.00 |
| Apr 15, 2026 | Barnes Wendy Lynn | See Remarks | M | 115,148 | $0.00 | $0.00 |
| Apr 15, 2026 | Barnes Wendy Lynn | See Remarks | F | 50,021 | $2.23 | $111.5K |
| Apr 15, 2026 | Barnes Wendy Lynn | See Remarks | M | 115,148 | $0.00 | $0.00 |
| Apr 15, 2026 | McGinnis Christopher A | See Remarks | F | 10,745 | $2.23 | $24.0K |
| Apr 15, 2026 | McGinnis Christopher A | See Remarks | M | 36,987 | $0.00 | $0.00 |
| Apr 15, 2026 | McGinnis Christopher A | See Remarks | A | 36,987 | $0.00 | $0.00 |
| Mar 12, 2026 | REY-GIRAUD AGNES | Director | M | 192,185 | $0.4700 | $90.3K |
| Mar 12, 2026 | REY-GIRAUD AGNES | Director | G | 75,219 | $0.00 | $0.00 |
| Mar 12, 2026 | REY-GIRAUD AGNES | Director | M | 192,185 | $0.00 | $0.00 |
| Mar 8, 2026 | Nabiey Romin | Chief Accounting Officer | M | 10,201 | $0.00 | $0.00 |
| Mar 8, 2026 | Nabiey Romin | Chief Accounting Officer | F | 4,201 | $2.28 | $9.6K |
| Mar 8, 2026 | Nabiey Romin | Chief Accounting Officer | M | 10,201 | $0.00 | $0.00 |
| Mar 3, 2026 | Nabiey Romin | Chief Accounting Officer | A | 108,189 | $0.00 | $0.00 |
| Feb 15, 2026 | Nabiey Romin | Chief Accounting Officer | M | 4,804 | $0.00 | $0.00 |
| Feb 15, 2026 | McGinnis Christopher A | See Remarks | M | 179,120 | $0.00 | $0.00 |
| Feb 15, 2026 | McGinnis Christopher A | See Remarks | F | 52,799 | $2.18 | $115.1K |
| Feb 15, 2026 | McGinnis Christopher A | See Remarks | M | 179,120 | $0.00 | $0.00 |
| Feb 15, 2026 | Nabiey Romin | Chief Accounting Officer | M | 4,804 | $0.00 | $0.00 |
| Feb 15, 2026 | Nabiey Romin | Chief Accounting Officer | F | 1,979 | $2.18 | $4.3K |
| Feb 8, 2026 | Nabiey Romin | Chief Accounting Officer | M | 12,663 | $0.00 | $0.00 |
| Feb 8, 2026 | Nabiey Romin | Chief Accounting Officer | F | 5,215 | $2.44 | $12.7K |
| Feb 8, 2026 | Nabiey Romin | Chief Accounting Officer | M | 12,663 | $0.00 | $0.00 |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 1 mixed, 2 neutral. Avg impact: 4.3/10.
MIXED
8-K
5/10
GoodRx reported Q1 2026 revenue of $194.0M (-4% YoY), GAAP EPS of $0.00 (miss vs $0.03 consensus), a
May 6, 2026
NEUTRAL
8-K
3/10
GoodRx Holdings appointed Thomas Chan as Chief Accounting Officer, effective April 23, 2026. Chan, p
Apr 24, 2026
NEUTRAL
8-K
2/10
GoodRx director Ian T. Clark resigned effective March 31, 2026, with no disagreement cited. CEO Wend
Apr 3, 2026
BEARISH
8-K
7/10
GoodRx reported in-line Q4 and full-year 2025 results with $796.9M revenue (+1% YoY) and $270.5M Adj
Feb 25, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Hold (48% buy). Based on 21 analysts: 4 strong buy, 6 buy, 9 hold, 2 sell, 0 strong sell.
Analyst Price Targets
$3.18 mean target
+20.0% upside
Strong Buy (3.00)
$2.25 Low
$4.00 High
| Metric | Value |
|---|---|
| Current Price | $2.65 |
| Target Low | $2.25 |
| Target Mean | $3.18 |
| Target Median | $3.00 |
| Target High | $4.00 |
| # Analysts | 13 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.08 | $0.07 | $0.11 | -10.5% | +1.3% | 3↑ 5↓ | $0.2B | -4.9% | 11 |
| Next Q 2026-09-30 |
$0.08 | $0.07 | $0.09 | 1.3% | -3.6% | 2↑ 7↓ | $0.2B | -1.1% | 11 |
| Current FY 2026-12-31 |
$0.31 | $0.29 | $0.35 | -11.2% | -1.9% | 3↑ 7↓ | $0.8B | -2.6% | 11 |
| Next FY 2027-12-31 |
$0.36 | $0.30 | $0.44 | 15.5% | -2.4% | 3↑ 6↓ | $0.8B | 5.5% | 12 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.081 | |
| 7d ago | $0.082 | -0.001 |
| 30d ago | $0.080 | +0.001 |
| 60d ago | $0.080 | +0.000 |
| 90d ago | $0.103 | -0.022 |
8 analyst firms have rated this stock: 0 upgrades, 2 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 14, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| May 11, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| Mar 4, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Mar 3, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 2, 2026 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| Feb 27, 2026 | Mizuho | MAINTAIN | Neutral | Neutral |
| Feb 27, 2026 | JP Morgan | DOWNGRADE | Overweight | Neutral |
| Jan 22, 2026 | Jefferies | DOWNGRADE | Buy | Hold |
| Jan 9, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Dec 18, 2025 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 6 | 9 | 2 | 0 | 48% | |
| May 1, 2026 | 4 | 6 | 9 | 2 | 0 | 48% | |
| Apr 1, 2026 | 4 | 6 | 9 | 2 | 0 | 48% | |
| Mar 1, 2026 | 4 | 6 | 9 | 2 | 0 | 48% | |
| Feb 1, 2026 | 4 | 7 | 8 | 2 | 0 | 52% | |
| Jan 1, 2026 | 5 | 7 | 7 | 2 | 0 | 57% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
GoodRx, a turn around opportunity. ($GDRX)
▲ 1
💬 0
⚡ 0.5
May 27, 2026
short_volume
Short Volume: GDRX — 59.3% short (0.6M / 0.9M)
Short: 562,062 | Exempt: 129 | TRF Vol: 947,036 | Short Ratio: 59.3% | Off-exchange volume (dark pool + OTC)
May 26, 2026
short_volume
Short Volume: GDRX — 55.7% short (1.0M / 1.8M)
Short: 1,026,492 | Exempt: 24,024 | TRF Vol: 1,841,792 | Short Ratio: 55.7% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: GDRX — 56.8% short (0.3M / 0.5M)
Short: 294,429 | Exempt: 27 | TRF Vol: 518,310 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings_calendar
GDRX Q1 2026 Earnings Before Market Open — 2026-05-07
May 6, 2026
earnings_calendar
GDRX Q1 2026 Earnings Before Market Open — 2026-05-06
Apr 13, 2026
short_volume
Short Volume: GDRX — 56.9% short (0.3M / 0.6M)
Short: 337,542 | Exempt: 0 | TRF Vol: 593,579 | Short Ratio: 56.9% | Off-exchange volume (dark pool + OTC)
Feb 27, 2026
short_interest
FTD: GDRX — 490,881 shares ($1.0M) failed to deliver
Settlement: 20260227, Price: $1.99, FTD Value: $976,853.19, GOODRX HLDGS INC COM CL A
Feb 25, 2026
earnings_calendar
GDRX Q4 2025 Earnings After Market Close — 2026-02-25
Feb 6, 2026
short_interest
FTD: GDRX — 395,634 shares ($0.9M) failed to deliver
Settlement: 20260206, Price: $2.29, FTD Value: $906,001.86, GOODRX HLDGS INC COM CL A